Lansoprazole
- Generic Name
- Lansoprazole
- Brand Names
- Prevacid, Prevpac
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 103577-45-3
- Unique Ingredient Identifier
- 0K5C5T2QPG
- Background
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other patholog...
- Indication
Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of sever...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
- Associated Therapies
- -
Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Incheon St.Mary's Hospital
- Target Recruit Count
- 217
- Registration Number
- NCT04674774
- Locations
- 🇰🇷
Incheon St. Mary's Hospital, Incheon, Korea, Republic of
Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT04531475
- Locations
- 🇨🇳
Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
🇨🇳Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 14
- Registration Number
- NCT04453189
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 42
- Registration Number
- NCT04188119
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 1046
- Registration Number
- NCT04167670
- Locations
- 🇺🇸
Carolina Research, Greenville, North Carolina, United States
🇺🇸Synexus Clinical Research US, Inc. - Anderson, Anderson, South Carolina, United States
🇺🇸Anaheim Clinical Trials LLC, Anaheim, California, United States
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 1027
- Registration Number
- NCT04124926
- Locations
- 🇺🇸
Carolina Research, Greenville, North Carolina, United States
🇺🇸Central Sooner Research, Norman, Oklahoma, United States
🇺🇸Biopharma Informatic, LLC, Houston, Texas, United States
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 48
- Registration Number
- NCT03487562
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT03468777
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Cardiac Safety of Lansoprazole and Domperidon Combination
- Conditions
- Interventions
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
- Registration Number
- NCT03355170
- Locations
- 🇹🇷
Dr. Sadi Konuk Research and Training Hospital Gastroenterology Dep., Istanbul, Turkey
🇹🇷Tepecik Research and Training Hospital Gastroenterology Dep., İzmir, Turkey
🇹🇷Cumhuriyet University Medical Faculty Gastroenterology Dep., Sivas, Turkey
Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 43
- Registration Number
- NCT03192059
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪University Hospital Antwerp, Antwerp, Belgium
🇧🇪University Hospital Gent, Gent, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.